Brightseed, which uses AI to discover bioactive health ingredients, has debuted BioMetaControl for metabolic health. The launch marks Brightseed’s expansion beyond digestive health into the trending blood glucose management and metabolic support categories.  

Brightseed said its proprietary AI platform, Forager, identified HNF4-alpha as the “master metabolic switch” that plays a pivotal role in blood glucose regulation. Forager also predicted bioactives, n-trans-Caffeoyl Tyramine (NCT) and n-trans-Feruloyl Tyramine (NFT), as potent HNF4-alpha agonists. These bioactives have been tested in vivo and validated for their role in HNF4-alpha agonism, the company said.

“BioMetaControl is a pivotal milestone for Brightseed as we expand into metabolic health, building on our foundation in digestive wellness and further proving Forager’s discovery capabilities,” said Lee Chae, co-founder and CEO of Brightseed. “We are excited to provide brands with a clinically proven, nature-powered solution that supports blood glucose control and complements the use of GLP-1 therapies.” 

By activating HNF4α, bioactives in BioMetaControl have been shown to address three key consumer and GLP-1 user needs: 

• Glucose Control: Support for healthy all-day and post-meal blood sugar levels, reduces glucose variability, and improves fasting blood glucose. 
• Sustained Energy: Help stabilizing blood sugar to minimize spikes and crashes, supporting energy throughout the day (based on study subject testimonials).
• Digestive Relief: Bioactives NCT and NFT have been shown to reduce bloating and GI discomfort, common challenges for GLP-1 users, in a separate study. 

Benefits for Glucose Control

In a recent randomized, double-blind, parallel-arm, clinical study (n=126), NCT and NFT administered as BioMetaControl demonstrated a statistically significant improvement in fasting blood glucose, fasting insulin, and post-meal glucose levels in prediabetic subjects. BioMetaControl was found to improve these parameters in 30 days. 

These improvements were not only found in outcomes that represent a snapshot in time, such as fasting blood glucose, fasting insulin levels, and post-meal blood glucose levels, but also in measures of continuous glucose monitoring over a period of 24 hours. 

The study results have been submitted to a peer-reviewed journal and are expected to be published in Q4 2025, the company said. In a separate, peer-reviewed, and published study NCT and NFT at the same dose demonstrated digestive relief benefits emerging in under three weeks. 

At a daily dose of 120 mg, BioMetaControl can be applied to capsule, tablet, soft gel, or functional beverage formulations.